PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 11, 2019New England Journal of Medicine869 citationsOpen Access

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

View Full Paper
DSDennis J. SlamonPNPatrick NevenSCStephen Chia

Key Points

  • This research aims to evaluate the survival benefits of ribociclib plus fulvestrant compared to placebo plus fulvestrant in advanced breast cancer.
  • Participants included patients with hormone-receptor-positive, HER2-negative advanced breast cancer.
  • The study was funded by Novartis and registered under ClinicalTrials.gov number NCT02422615.
  • Ribociclib plus fulvestrant demonstrated a significant overall survival benefit compared to placebo plus fulvestrant.

Abstract

Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor-positive, HER2-negative advanced breast cancer. (Funded by Novartis; MONALEESA-3 ClinicalTrials.gov number, NCT02422615.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Slamon et al. (2019) studied this question.

synapsesocial.com/papers/69d8d9b0d2f7327e70ae46b1https://doi.org/10.1056/nejmoa1911149
Ask AI
Helpful
Bookmark
Share
View Full Paper